Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Microbiome
42 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
Microbiome
Modifying the Gut Microbiome to Improve CAR-T, HSCT, and Other Therapeutic Responses
PAO-10-23-CL-07
Microbiome Therapeutic Innovation
Unleashing the Power of the Microbiome: Advancements, Challenges, and the Therapeutic Future
PAO-03-23-CL-08
Microbiome-Based CDMO
Expanding a Leadership Position in Microbiome-Based Contract Development and Manufacturing
PAO-11-022-CL-13
Diabetes Research
Composition of Gut Microbiome Predicts the Onset of Type 2 Diabetes
PR-M02-22-13
Live Biotherapeutic Products
Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives
PAO-09-21-CL-11
Live Biotherapeutic Products
Design Considerations for Live Biotherapeutic Product Facilities Working with Spore-Forming Bacteria
PAO-06-21-CL-10
Live Biotherapeutic Products
Framing the Narrative on CMC Development for Microbiome Therapeutics
PAO-06-21-CL-05
Microbiome
Understanding the Link Between Gut Health and Disease
PTV-05-21-CL-004
COVID-19 Impacts
Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?
PAO-03-21-NI-01
Manufacturing Facility
Arranta Bio Announces Addition of 130,000 sq. ft. Boxborough, Mass., Manufacturing Facility to Supply Clinical and Commercial Microbiome Products for Clients and Closes Series B Equity Financing
PR-M03-21-002
Corporate Social Responsibility
Life Imitating Science: Arranta Bio’s Commitment to Corporate Social Responsibility and Diversity
PAP-Q4-20-CL-002
The Future of Healthcare
How Does Arranta Bio Envision the Future of the Pharma/Biopharma Industry?
PAP-Q4-20-RT2-007
Gene Editing
Enhancing Human Gut Tissue Models through Gene Editing
PAO-11-20-CL-03
Microbiome
Evaluating Microbiome Therapies with Intestinal Cell Models
PAO-10-20-CL-02
Microbiome CDMO
Extensive Experience Is Crucial to Speed to the Clinic and Market for Live Biotherapeutic Products
PAP-Q3-20-CL-004
Design Logic
Experience to Solve Your Microbiome Challenges
PAP-Q3-20-NI-010
The Future of Healthcare
How Is Arranta Bio Evolving its Business Model to Meet the Future of Healthcare?
PAP-Q3-20-RT2-009
Microbiome
Selecting a Microbiome CDMO Partner for the Long Term
PAP-Q2-20-CL-008
Microbiome
Reflections on a 10-Year Journey in the Microbiome
PAP-Q1-20-CL-006
Microbiota
Proving the Link Between the Microbiota and the Human Immune System in Non-Human Primates
PAP-Q1-20-CL-021
The Future of Healthcare
How is Arranta Bio Preparing to Face the Future of Healthcare?
PAP-Q1-20-R2-005
Microbiome
Cynbiose Receives $2.1 Million to Launch CYNBIOME for Preclinical Services for the Microbiome
PR-M01-20-NI-042
Microbiome
LNC Therapeutics Chooses Luina Bio for the Development and GMP Manufacturing of its First Live Biotherapeutic Product Based on the Gut Microbiome
PR-M01-20-NI-009
Microbiome
Supporting Commercialization of Live Biotherapeutic Products for Microbiome-Based Therapies
PAP-Q4-19-CL-009
1
2
»
.svg)